GlassScriptPhysician profile
Ehren Kilpatrick
NPI 1487287447
$3,988.72
in general payments reported to CMS, 2019-2025
37 companies · $1,266 in 2025
The $1,266 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $572 · 2022: $606 · 2023: $819 · 2024: $726 · 2025: $1,266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,532 · Education: $185 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,531.53 |
| Education | $185.16 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $449.31 | 2024-2025 | Tremfya |
| Amgen INC. | $432.91 | 2021-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $375.23 | 2023-2025 | Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $361.50 | 2021-2025 | Xifaxan, Trulance, Cycloset |
| Novo Nordisk INC | $304.83 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.68 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Paratek Pharmaceuticals, INC. | $238.20 | 2021-2025 | Nuzyra |
| Lilly USA, LLC | $173.87 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Esperion Therapeutics, INC. | $139.17 | 2021-2025 | Nexletol |
| Antares Pharma, INC. | $132.66 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Csl Behring | $99.29 | 2021 | |
| Becton, Dickinson and Company | $94.00 | 2024-2025 | Power-Trialysis, Sherlock |
| Abbvie INC. | $91.33 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.54 | 2021-2022 | |
| Exact Sciences Corporation | $69.67 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $67.56 | 2023 | Aplenzin |
| Novartis Pharmaceuticals Corporation | $64.35 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $62.60 | 2025 | Quviviq |
| Glaxosmithkline, LLC. | $45.95 | 2021-2024 | Trelegy Ellipta |
| Smith+Nephew, INC. | $45.00 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.19 | 2022 | |
| Janssen Pharmaceuticals, INC | $41.15 | 2023-2025 | Tremfya, Xarelto |
| Tolmar, INC. | $39.68 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $39.66 | 2021 | |
| Boston Scientific Corporation | $34.47 | 2025 | Watchman Access System |
| Adlon Therapeutics L.P. | $27.34 | 2021 | |
| Pfizer INC. | $23.92 | 2023 | |
| Sanofi Pasteur INC. | $21.82 | 2023 | |
| Phathom Pharmaceuticals, INC. | $20.46 | 2024 | Voquezna |
| Dexcom, INC. | $18.28 | 2024 | Dexcom G6 Transmitter |
| Melinta Therapeutics, LLC | $17.94 | 2021 | |
| Merck Sharp & Dohme LLC | $17.64 | 2021 | |
| Halozyme INC | $17.05 | 2023 | |
| Ucb, INC. | $15.04 | 2021 | |
| Eisai INC. | $15.03 | 2022 | |
| Astellas Pharma US INC | $14.98 | 2024 | Veozah |
| Mayne Pharma Commercial LLC | $13.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ehren Kilpatrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.